Sujata Tyagi Dayal Sells 13,761 Shares of Emergent Biosolutions (NYSE:EBS) Stock

Emergent Biosolutions Inc. (NYSE:EBS) Director Sujata Tyagi Dayal sold 13,761 shares of the firm’s stock in a transaction dated Friday, May 1st. The stock was sold at an average price of $8.40, for a total value of $115,592.40. Following the completion of the transaction, the director owned 100,563 shares of the company’s stock, valued at approximately $844,729.20. The trade was a 12.04% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Emergent Biosolutions Trading Up 6.1%

Emergent Biosolutions stock opened at $9.06 on Wednesday. The stock has a 50-day moving average price of $8.50 and a 200 day moving average price of $10.30. The company has a market capitalization of $467.70 million, a price-to-earnings ratio of -32.35 and a beta of 2.33. Emergent Biosolutions Inc. has a 52 week low of $4.71 and a 52 week high of $14.06. The company has a quick ratio of 2.08, a current ratio of 4.29 and a debt-to-equity ratio of 1.10.

Emergent Biosolutions (NYSE:EBS) last posted its quarterly earnings results on Thursday, April 30th. The biopharmaceutical company reported $0.21 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.25) by $0.46. Emergent Biosolutions had a negative net margin of 1.27% and a positive return on equity of 10.76%. The company had revenue of $156.10 million during the quarter, compared to analyst estimates of $145.00 million.

Wall Street Analysts Forecast Growth

EBS has been the subject of a number of research reports. HC Wainwright decreased their target price on shares of Emergent Biosolutions from $15.00 to $12.00 and set a “buy” rating for the company in a research report on Monday, March 9th. Weiss Ratings downgraded Emergent Biosolutions from a “sell (d+)” rating to a “sell (d)” rating in a research report on Monday, April 27th. Finally, Wall Street Zen cut Emergent Biosolutions from a “buy” rating to a “hold” rating in a report on Sunday, March 8th. One investment analyst has rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the company has a consensus rating of “Hold” and a consensus target price of $12.00.

Hedge Funds Weigh In On Emergent Biosolutions

Several institutional investors have recently made changes to their positions in EBS. Legal & General Group Plc acquired a new position in shares of Emergent Biosolutions in the 2nd quarter valued at $31,000. Torren Management LLC purchased a new stake in Emergent Biosolutions during the fourth quarter worth $37,000. CANADA LIFE ASSURANCE Co acquired a new stake in Emergent Biosolutions during the fourth quarter valued at $45,000. Raymond James Financial Inc. purchased a new position in Emergent Biosolutions in the second quarter valued at $53,000. Finally, Farther Finance Advisors LLC increased its holdings in Emergent Biosolutions by 361.3% in the fourth quarter. Farther Finance Advisors LLC now owns 6,163 shares of the biopharmaceutical company’s stock valued at $76,000 after buying an additional 4,827 shares in the last quarter. 78.40% of the stock is owned by hedge funds and other institutional investors.

Key Headlines Impacting Emergent Biosolutions

Here are the key news stories impacting Emergent Biosolutions this week:

• Positive Sentiment: Q1 results beat consensus — Emergent reported $0.21 EPS vs. a consensus loss and revenue of $156.1M vs. ~$145M expected, which provides fundamental support for the stock. MarketBeat EBS coverage
• Neutral Sentiment: Directors reported the sales were executed under pre-arranged Rule 10b5-1 plans — a disclosure that typically reduces the negative signal from insider selling because trades were planned in advance. InsiderTrades alert
• Negative Sentiment: Director Kathryn C. Zoon sold 17,202 shares (~17.7% reduction of her holding) at about $8.40 per share — a sizable individual sale that could be perceived negatively by some investors. Zoon sale article
• Negative Sentiment: Director Keith Katkin sold 15,481 shares (?13.9% reduction) at roughly $8.28 per share — another material director sale disclosed this week. Katkin sale article
• Negative Sentiment: Director Donald W. Degolyer sold 15,481 shares (?10.7% reduction) at about $8.40 per share — adds to the cluster of director selling. Degolyer sale article
• Negative Sentiment: Director Sujata Tyagi Dayal sold 13,761 shares (?12.0% reduction) at an average ~$8.40; filing notes the director still holds a six-figure stake and the sale was under a 10b5-1 plan. Dayal sale article

About Emergent Biosolutions

Emergent BioSolutions is a global specialty biopharmaceutical company focused on developing, manufacturing and commercializing medical countermeasures and specialty products that address public health threats. The company’s portfolio includes vaccines, antibody therapies and critical care products designed to protect against biological, chemical and emerging infectious disease threats. Emergent has longstanding partnerships with government agencies, including the U.S. Department of Defense and the Biomedical Advanced Research and Development Authority (BARDA), to support national preparedness programs.

Key commercial products in Emergent’s lineup include BioThrax (anthrax vaccine adsorbed), ACAM2000 (smallpox vaccine) and Vaxchora (cholera vaccine), alongside therapeutic treatments such as Anthrasil (anthrax immune globulin) and the naloxone-based nasal spray Narcan for opioid overdose reversal.